1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nicox S.A.

Nicox S.A.

NICXF
Nicox S.A.US flagOther OTC
0.30
USD
-NaN
- -
30.94MMarket Cap
Nicox S.A.
NICXF
(Other OTC)

Recent

price

0.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.51
- -
0.52
0.03
0.37
- -
- -
0.56
0.16
0.27
0.43
0.23
0.1
0.14
0.11
0.19
0.05
Revenue per Share
-3.03
-1.14
-0.7
-1.22
-1.43
-1.25
-0.8
-0.13
-0.62
-0.62
-0.54
-1.17
-0.62
-0.42
-0.32
-0.03
-1.22
Basic EPS, GAAP
-2.87
-0.98
-0.79
-1.37
-2.13
-1.13
-1.08
-0.46
-0.66
-0.53
-0.16
-0.49
-0.46
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1
1
1
1.02
-0.2
-0.23
-16.32
-14.4
-13.64
-13.76
-12.76
-12.42
-9.73
-10.19
-7.58
-6.04
1.02
Book Value per Share
6.9
5.79
4.99
3.56
-0.86
-1.03
-0.03
1.28
0.57
0.37
0.37
0.27
0.84
0.43
0.05
0.07
3.57
Tangible Book Value per Share
14
15
15
15
16
22
24
27
30
30
34
37
50
50
70
88
15
Basic Weighted Avg Shares
7
- -
8
- -
6
- -
- -
15
5
8
14
9
5
7
8
17
1
Sales/Revenue/Turnover
-592.71
- -
-112.91
-3,312.61
-436.52
-24,959.7
-128,225
-113.06
-444.56
-221.84
-48.62
-211.65
-560.3
-203.14
-108.4
-81.33
-2,813.12
Operating Margin (%)
1
2
1
1
2
- -
- -
- -
- -
1
2
29
11
- -
- -
18
- -
Depreciation Expense
-44
-17
-10
-18
-23
-28
-19
-4
-18
-19
-18
-44
-31
-21
-22
-2
-18
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-592.09
- -
-133.82
-4,080.96
-387.19
-41,700
-118,968.75
-23.99
-389.89
-229.08
-125.48
-509.86
-596.81
-302.48
-284.9
-14.39
-2,381.93
Profit Margin (%)
102
88
74
53
29
11
17
36
18
22
37
40
63
46
21
8
53
Working Capital
- -
- -
- -
- -
- -
1
- -
- -
- -
10
13
21
25
26
18
- -
- -
LT Debt
100
84
75
61
96
101
105
127
114
109
101
76
42
21
3
6
61
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-303.71
-114.61
-69.93
-120.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-120.87
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
177
204
166

Working Capital

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
Total Current Assets
70
66
61
Cash, Cash Equivalents & STI
67
64
58
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
1
Total Current Liabilities
4
4
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-12.36%
-25.22%
76.4%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
29.2%
-0.39%
-89.22%
Sales/Revenue/Turnover
9,423.44%
15.9%
113.41%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
7
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
17

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.42
2024
- -
- -
- -
- -
-0.32
2025
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Metacrine, Inc. (MTCR)
Adial Pharmaceuticals, Inc. (ADIL)
Nanoform Finland Oyj (NANOFH.HE)
Onesource Specialty Pharma Ltd. (ONESOURCE.NS)
TScan Therapeutics, Inc. (TCRX)
Verve Therapeutics, Inc. (VERV)
Business
Nicox S.A. (Ticker: NICXF) is a France-based international ophthalmology company that develops and commercializes innovative therapeutics to maintain vision and improve ocular health; its core offerings include VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% for open-angle glaucoma or ocular hypertension and ZERVIATE (cetirizine ophthalmic solution) 0.24% for ocular itching associated with allergic conjunctivitis, both commercialized in the U.S. and with ZERVIATE also launched in China; the company's pipeline features NCX 470, a nitric oxide-donating bimatoprost analog that has completed Phase 3 trials for glaucoma in the U.S. and China with an ongoing Phase 3 program in Japan, NCX 4251, a fluticasone propionate suspension in clinical development for dry eye disease licensed exclusively to a partner in China, and NCX 1728 under preclinical evaluation for retinal conditions. Founded in 1996 and headquartered in Sophia Antipolis (Biot), France, Nicox operates globally with subsidiaries including Nicox Ophthalmics, Inc. in Durham, North Carolina, U.S., and Nicox Research Institute S.r.l. in Bresso, Italy, targeting eye care practitioners and patients through partnerships with Bausch & Lomb, Kowa, Eyevance Pharmaceuticals, and Ocumension Therapeutics. Recent developments include the July 2025 agreement with Kowa granting exclusive rights to NCX 470 in the U.S. and all unlicensed territories for up to €191.5 million, positive 12-month sustained efficacy data from the NCX 470 Denali Phase 3 trial in October 2025 with no new safety signals, and the first commercial sale of ZERVIATE in China by partner Ocumension in December 2024, establishing a new recurrent revenue stream following Ocumension's market-enhancing acquisitions.

Company News

APIChat

  • defenseworld.net

    Short Interest in Nicox SA (OTCMKTS:NICXF) Rises By 1,904.8%

  • zacks.com

    Nicox (NICXF) Upgraded to Buy: Here's Why

  • globenewswire.com

    Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

  • zacks.com

    Nicox SA (NICXF) Upgraded to Buy: Here's What You Should Know